Changes

no edit summary
Line 4: Line 4:  
{{Under Construction}}
 
{{Under Construction}}
   −
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Splenic Marginal Zone Lymphoma]].
+
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Splenic Marginal Zone Lymphoma]].
 
}}</blockquote>
 
}}</blockquote>
 +
 +
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
 +
 
==Primary Author(s)*==
 
==Primary Author(s)*==
   Line 13: Line 16:  
==Cancer Category / Type==
 
==Cancer Category / Type==
   −
*[[Mature B-Cell Neoplasms]]
+
*[[HAEM4:Mature B-Cell Neoplasms]]
    
==Cancer Sub-Classification / Subtype==
 
==Cancer Sub-Classification / Subtype==
Line 168: Line 171:  
|BRAF mutations
 
|BRAF mutations
 
|Diagnostic (exclusion)
 
|Diagnostic (exclusion)
|Present in [[Hairy Cell Leukemia|hairy cell leukemia (HCL)]] and absent in SMZL<ref>{{Cite journal|last=Naseem|first=Shano|last2=Gupta|first2=Ojas|last3=Binota|first3=Jogeshwar|last4=Varma|first4=Neelam|last5=Varma|first5=Subhash|last6=Malhotra|first6=Pankaj|date=2020|title=BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system|url=http://link.springer.com/10.1007/s11033-020-05509-0|journal=Molecular Biology Reports|language=en|doi=10.1007/s11033-020-05509-0|issn=0301-4851}}</ref>
+
|Present in [[HAEM5:Hairy cell leukaemia|hairy cell leukemia (HCL)]] and absent in SMZL<ref>{{Cite journal|last=Naseem|first=Shano|last2=Gupta|first2=Ojas|last3=Binota|first3=Jogeshwar|last4=Varma|first4=Neelam|last5=Varma|first5=Subhash|last6=Malhotra|first6=Pankaj|date=2020|title=BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system|url=http://link.springer.com/10.1007/s11033-020-05509-0|journal=Molecular Biology Reports|language=en|doi=10.1007/s11033-020-05509-0|issn=0301-4851}}</ref>
 
|-
 
|-
 
|MYD88 mutations
 
|MYD88 mutations
 
|Diagnostic (exclusion)
 
|Diagnostic (exclusion)
|Present in [[Lymphoplasmacytic Lymphoma|lymphoplasmacytic lymphoma (LPL)]] and rare but not absent in SMZL
+
|Present in [[HAEM5:Lymphoplasmacytic lymphoma|lymphoplasmacytic lymphoma (LPL)]] and rare but not absent in SMZL
 
|-
 
|-
 
|t(11;14)(q13;q32)/IGH-CCND1*
 
|t(11;14)(q13;q32)/IGH-CCND1*
 
|Diagnostic (exclusion)
 
|Diagnostic (exclusion)
|Present in [[Mantle Cell Lymphoma|mantle cell lymphoma (MCL)]] and absent in SMZL
+
|Present in [[HAEM5:Mantle cell lymphoma|mantle cell lymphoma (MCL)]] and absent in SMZL
 
|-
 
|-
 
|t(14;18)(q32;q21)/IGH-BCL2
 
|t(14;18)(q32;q21)/IGH-BCL2
 
|Diagnostic (exclusion)
 
|Diagnostic (exclusion)
|Present in [[Follicular Lymphoma|follicular lymphoma (FL)]] and rare but not absent in SMZL<ref name=":1" />
+
|Present in [[HAEM5:Follicular lymphoma|follicular lymphoma (FL)]] and rare but not absent in SMZL<ref name=":1" />
 
|-
 
|-
 
|t(11;18)(q21;q21)/BIRC3-MALT1
 
|t(11;18)(q21;q21)/BIRC3-MALT1
 
|Diagnostic (exclusion)
 
|Diagnostic (exclusion)
|Present in [[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)|MALT lymphoma]] and absent in SMZL
+
|Present in [[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] and absent in SMZL
 
|-
 
|-
 
|t(14;18)(q32;q21)/IGH-MALT1
 
|t(14;18)(q32;q21)/IGH-MALT1
 
|Diagnostic (exclusion)
 
|Diagnostic (exclusion)
|Present in [[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)|MALT lymphoma]] and absent in SMZL<ref>{{Cite journal|last=Streubel|first=Berthold|last2=Lamprecht|first2=Andrea|last3=Dierlamm|first3=Judith|last4=Cerroni|first4=Lorenzo|last5=Stolte|first5=Manfred|last6=Ott|first6=German|last7=Raderer|first7=Markus|last8=Chott|first8=Andreas|date=2003|title=T(14;18)(q32;q21) involving IGH andMALT1 is a frequent chromosomal aberration in MALT lymphoma|url=https://ashpublications.org/blood/article/101/6/2335/106539/T1418q32q21-involving-IGH-andMALT1-is-a-frequent|journal=Blood|language=en|volume=101|issue=6|pages=2335–2339|doi=10.1182/blood-2002-09-2963|issn=1528-0020}}</ref>
+
|Present in [[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] and absent in SMZL<ref>{{Cite journal|last=Streubel|first=Berthold|last2=Lamprecht|first2=Andrea|last3=Dierlamm|first3=Judith|last4=Cerroni|first4=Lorenzo|last5=Stolte|first5=Manfred|last6=Ott|first6=German|last7=Raderer|first7=Markus|last8=Chott|first8=Andreas|date=2003|title=T(14;18)(q32;q21) involving IGH andMALT1 is a frequent chromosomal aberration in MALT lymphoma|url=https://ashpublications.org/blood/article/101/6/2335/106539/T1418q32q21-involving-IGH-andMALT1-is-a-frequent|journal=Blood|language=en|volume=101|issue=6|pages=2335–2339|doi=10.1182/blood-2002-09-2963|issn=1528-0020}}</ref>
 
|-
 
|-
 
|t(1;14)(p22;q32)/IGH-BCL10
 
|t(1;14)(p22;q32)/IGH-BCL10
 
|Diagnostic (exclusion)
 
|Diagnostic (exclusion)
|Present in [[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)|MALT lymphoma]] and absent in SMZL
+
|Present in [[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]] and absent in SMZL
 
|}
 
|}
 
<nowiki>*</nowiki>Cases previously reported as SMZL with IGH-CCND1 fusion should now be classified as MCL
 
<nowiki>*</nowiki>Cases previously reported as SMZL with IGH-CCND1 fusion should now be classified as MCL
Line 465: Line 468:  
==Links==
 
==Links==
   −
*[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]]
+
*[[HAEM4:Splenic B-cell Lymphoma/Leukemia, Unclassifiable]]
*[[Splenic Diffuse Red Pulp Small B-cell Lymphoma]]
+
*[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma]]
    
==References==
 
==References==